China Meheco subsidiary's vitamin B6 injection passes evaluation

Tianfang Pharmaceutical, a wholly-owned subsidiary of China Meheco, announced it received a supplemental drug application approval for its vitamin B6 injection from the National Medical Products Administration. This approval confirms that the drug, with specifications of 1ml:0.1g, has passed the generic drug quality and efficacy consistency evaluation. The drug is classified as a chemical drug and is approved for additional specifications.

Vitamin B6 injection is primarily used for the prevention and treatment of vitamin B6 deficiency, as well as for conditions such as isoniazide poisoning, pregnancy-related vomiting, radiogenic illness, and chemotherapy-induced vomiting. The original drug was developed by Japan's Fujisawa Pharmaceutical Co. in 1957. As of the disclosure date, Tianfang Pharmaceutical's vitamin B6 injection project incurred a cumulative investment of approximately 4.12 million yuan (unaudited).

According to third-party database Miny.net, domestic sales of vitamin B6 injection in public hospitals and grassroots medical terminals amounted to approximately 435 million yuan in 2024. Tianfang Pharmaceutical's sales of the drug in 2024 were approximately 4.93 million yuan (unaudited). The company anticipates this approval will boost the drug's market share and competitiveness.